<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PEN</journal-id>
<journal-id journal-id-type="hwp">sppen</journal-id>
<journal-id journal-id-type="nlm-ta">JPEN J Parenter Enteral Nutr</journal-id>
<journal-title>Journal of Parenteral and Enteral Nutrition</journal-title>
<issn pub-type="ppub">0148-6071</issn>
<issn pub-type="epub">1941-2444</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0148607111428324</article-id>
<article-id pub-id-type="publisher-id">10.1177_0148607111428324</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Invited Commentaries</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Long Road to Optimizing the Parenteral Provision of Nutrients</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Fukatsu</surname><given-names>Kazuhiko</given-names></name>
<degrees>MD, PhD</degrees>
</contrib>
<aff id="aff1-0148607111428324">Surgical Center, University of Tokyo Hospital, Tokyo, Japan</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0148607111428324">Kazuhiko Fukatsu, MD, PhD, Surgical Center, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Japan; e-mail: <email>fukatsu-1su@h.u-tokyo.ac.jp</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>36</volume>
<issue>2</issue>
<fpage>157</fpage>
<lpage>158</lpage>
<permissions>
<copyright-statement>© 2012 The American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>Parenteral nutrition (PN) is one of the greatest inventions in modern medicine. With PN, certain patient populations who cannot tolerate or receive enteral nutrition (EN) are given a good chance to survive because progressive malnutrition can be avoided. Without PN, many advances in surgery and critical care, on which we physicians today rely, would never have been realized.</p>
<p>Nevertheless, because of its nonphysiological properties, a number of PN-induced changes have been clinically and experimentally observed, and some of these changes can even be life-threatening.<sup><xref ref-type="bibr" rid="bibr1-0148607111428324">1</xref>,<xref ref-type="bibr" rid="bibr2-0148607111428324">2</xref></sup> The best way to avoid a PN-associated adverse event is to deliver nutrients via the gut. The higher the ratio of EN to PN, the more restoration of gut immunity can be expected.<sup><xref ref-type="bibr" rid="bibr3-0148607111428324">3</xref></sup> However, we prescribe PN for patients because they cannot tolerate EN. We need other alternatives to EN to prevent PN-induced host defense impairment and organ dysfunction.</p>
<p>To discover and apply such EN alternatives, we must thoroughly investigate what is happening during PN without enteral delivery of nutrients. Through what mechanisms does absence of PN reduce gut and systemic mucosal immunity, hepatic mononuclear cell number and functions, peritoneal host defense, and resistance to gut ischemia-reperfusion injury?<sup><xref ref-type="bibr" rid="bibr1-0148607111428324">1</xref>,<xref ref-type="bibr" rid="bibr4-0148607111428324">4</xref>-<xref ref-type="bibr" rid="bibr7-0148607111428324">7</xref></sup> Recent intensive research has unveiled possible answers to these questions. Blunted responses to stimuli due to a sort of immune paralysis and simultaneous exaggerated responses to stimuli, associated with reduced cytoprotection and increased endothelial activation, are both speculated to play key roles in increased vulnerability to various insults during PN.<sup><xref ref-type="bibr" rid="bibr4-0148607111428324">4</xref>,<xref ref-type="bibr" rid="bibr5-0148607111428324">5</xref>,<xref ref-type="bibr" rid="bibr8-0148607111428324">8</xref></sup></p>
<p>In this issue of the <italic>Journal of Parenteral and Enteral Nutrition</italic>, Li et al<sup><xref ref-type="bibr" rid="bibr9-0148607111428324">9</xref></sup> describe an anti–tumor necrosis factor α (TNF-α) monoclonal antibody treatment that prevents PN-associated liver disease (PNALD), in association with upregulation of adenosine triphosphate (ATP)–binding cassette transporter mRNA expression in this animal model. Although anti–TNF-α therapies have failed to improve clinical outcomes in patients with severe sepsis, infliximab, an anti–TNF-α monoclonal antibody, was found to be efficacious in treating inflammatory bowel diseases and rheumatoid arthritis.<sup><xref ref-type="bibr" rid="bibr9-0148607111428324">9</xref>,<xref ref-type="bibr" rid="bibr10-0148607111428324">10</xref></sup> PNALD is the most devastating complication of long-term PN.<sup><xref ref-type="bibr" rid="bibr2-0148607111428324">2</xref></sup> Once it develops, PNALD progresses to end-stage liver disease, leaving transplantation of both an intestine and a liver as the only viable life-saving option. Therefore, the present finding appears to give patients with long-term PN new hope of avoiding this potentially fatal complication.</p>
<p>However, we should be aware that research aimed at preventing PNALD with anti–TNF-α antibodies is only just beginning. First, we must keep in mind that only 7 days of PN were administered in this initial study. Effects of the antibody for longer durations of PN also need to be examined. Repeated injection might diminish its effects or even trigger allergic reactions. Second, because TNF-α is known to enhance host immunity, ablation of TNF-α functions by an exogenous antibody may impair host defenses against various pathogens. In fact, it has been demonstrated that TNF-α stimulates production of the polymeric immunoglobulin receptor, the protein required to transport immunoglobulin A (IgA) to mucosal surfaces.<sup><xref ref-type="bibr" rid="bibr11-0148607111428324">11</xref></sup> Blockade of TNF-α eliminated the normal respiratory IgA immune response to injury. Because PN impairs mucosal IgA-mediated defense by itself, the addition of TNF-α neutralization during PN may carry a risk of further damaging mucosal barrier function. Third, influences of TNF-α blockade on other PN-induced changes await clarification. Multiple factors are involved in PN-induced host defense impairment and organ dysfunction. Thus, whether anti–TNF-α therapy can also resolve other PN-related problems remains an open and very important question.</p>
<p>The goal of administering perfect PN is still far away. However, we have already traveled a long way on the road toward better PN and have discovered many useful strategies for reversing PN-induced changes. Addition of specific nutrients to PN formulas—for example, glutamine, arginine, ω-3 fatty acids, and butyric acid—and/or administrations of various neuropeptides and cytokines during PN may provide further advances in standard nutrition therapy.<sup><xref ref-type="bibr" rid="bibr1-0148607111428324">1</xref>,<xref ref-type="bibr" rid="bibr12-0148607111428324">12</xref>-<xref ref-type="bibr" rid="bibr14-0148607111428324">14</xref></sup> In this issue, another promising way to enhance nutrition management is described. It is these advances and insights that give physicians and patients hope.</p>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: none declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0148607111428324">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fukatsu</surname><given-names>K</given-names></name>
<name><surname>Kudsk</surname><given-names>KA</given-names></name>
</person-group>. <article-title>Nutrition and gut immunity</article-title>. <source>Surg Clin North Am</source>. <year>2011</year>;<volume>91</volume>:<fpage>755</fpage>-<lpage>770</lpage>.</citation>
</ref>
<ref id="bibr2-0148607111428324">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buchman</surname><given-names>AL</given-names></name>
<name><surname>Iyer</surname><given-names>K</given-names></name>
<name><surname>Fryer</surname><given-names>J</given-names></name>
</person-group>. <article-title>Parenteral nutrition–associated liver disease and the role for isolated intestine and intestine/liver transplantation</article-title>. <source>Hepatology</source>. <year>2006</year>;<volume>43</volume>:<fpage>9</fpage>-<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr3-0148607111428324">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ikezawa</surname><given-names>F</given-names></name>
<name><surname>Fukatsu</surname><given-names>K</given-names></name>
<name><surname>Moriya</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Reversal of parenteral nutrition–induced gut mucosal immunity impairment with small amounts of a complex enteral diet</article-title>. <source>J Trauma</source>. <year>2008</year>;<volume>65</volume>(<issue>2</issue>):<fpage>360</fpage>-<lpage>365</lpage>.</citation>
</ref>
<ref id="bibr4-0148607111428324">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moriya</surname><given-names>T</given-names></name>
<name><surname>Fukatsu</surname><given-names>K</given-names></name>
<name><surname>Maeshima</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Nutritional route affects ERK phosphorylation and cytokine production in hepatic mononuclear cells</article-title>. <source>Ann Surg</source>. <year>2007</year>;<volume>245</volume>(<issue>4</issue>):<fpage>642</fpage>-<lpage>650</lpage>.</citation>
</ref> <ref id="bibr5-0148607111428324">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ueno</surname><given-names>C</given-names></name>
<name><surname>Fukatsu</surname><given-names>K</given-names></name>
<name><surname>Kang</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Lack of enteral nutrition delays nuclear factor kappa B activation in peritoneal exudative cells in a murine glycogen-induced peritonitis model</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2006</year>;<volume>30</volume>(<issue>3</issue>):<fpage>179</fpage>-<lpage>185</lpage>.</citation>
</ref>
<ref id="bibr6-0148607111428324">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fukatsu</surname><given-names>K</given-names></name>
<name><surname>Zarzaur</surname><given-names>BL</given-names></name>
<name><surname>Johnson</surname><given-names>CD</given-names></name>
<name><surname>Lundberg</surname><given-names>AH</given-names></name>
<name><surname>Wilcox</surname><given-names>HG</given-names></name>
<name><surname>Kudsk</surname><given-names>KA</given-names></name>
</person-group>. <article-title>Enteral nutrition prevents remote organ injury and death after a gut ischemic insult</article-title>. <source>Ann Surg</source>. <year>2001</year>;<volume>233</volume>(<issue>5</issue>):<fpage>660</fpage>-<lpage>668</lpage>.</citation>
</ref>
<ref id="bibr7-0148607111428324">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>H</given-names></name>
<name><surname>Fan</surname><given-names>Y</given-names></name>
<name><surname>Teitelbaum</surname><given-names>DH</given-names></name>
</person-group>. <article-title>Intraepithelial lymphocyte-derived interferon-gamma evokes enterocyte apoptosis with parenteral nutrition in mice</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source>. <year>2003</year>;<volume>284</volume>(<issue>4</issue>):<fpage>G629</fpage>-<lpage>G637</lpage>.</citation>
</ref>
<ref id="bibr8-0148607111428324">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fukatsu</surname><given-names>K</given-names></name>
<name><surname>Lundberg</surname><given-names>AH</given-names></name>
<name><surname>Hanna</surname><given-names>MK</given-names></name>
<etal/>
</person-group>. <article-title>Route of nutrition influences intercellular adhesion molecule-1 expression and neutrophil accumulation in intestine</article-title>. <source>Arch Surg</source>. <year>1999</year>;<volume>134</volume>(<issue>10</issue>):<fpage>1055</fpage>-<lpage>1060</lpage>.</citation>
</ref>
<ref id="bibr9-0148607111428324">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>J</given-names></name>
<name><surname>Cai</surname><given-names>W</given-names></name>
<name><surname>Gong</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Anti–tumor necrosis factor–α monoclonal antibody alleviates parenteral nutrition–associated liver disease in mice</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2012</year>;<volume>36</volume>:<fpage>219</fpage>-<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr10-0148607111428324">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abraham</surname><given-names>E</given-names></name>
<name><surname>Glauser</surname><given-names>MP</given-names></name>
<name><surname>Butler</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: a randomized controlled multicenter trial. Ro 45-2081 Study Group</article-title>. <source>JAMA</source>. <year>1997</year>;<volume>277</volume>(<issue>19</issue>):<fpage>1531</fpage>-<lpage>1538</lpage>.</citation>
</ref>
<ref id="bibr11-0148607111428324">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hermsen</surname><given-names>JL</given-names></name>
<name><surname>Sano</surname><given-names>Y</given-names></name>
<name><surname>Gomez</surname><given-names>FE</given-names></name>
<etal/>
</person-group>. <article-title>Parenteral nutrition inhibits tumor necrosis factor-alpha-mediated IgA response to injury</article-title>. <source>Surg Infect (Larchmt)</source>. <year>2008</year>;<volume>9</volume>(<issue>1</issue>):<fpage>33</fpage>-<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr12-0148607111428324">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Murakoshi</surname><given-names>S</given-names></name>
<name><surname>Fukatsu</surname><given-names>K</given-names></name>
<name><surname>Omata</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Effects of adding butyric acid to total parenteral nutrition on gut-associated lymphoid tissue and mucosal immunoglobulin A levels</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2011</year>;<volume>35</volume>(<issue>4</issue>):<fpage>465</fpage>-<lpage>472</lpage>.</citation>
</ref>
<ref id="bibr13-0148607111428324">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>DeWitt</surname><given-names>RC</given-names></name>
<name><surname>Wu</surname><given-names>Y</given-names></name>
<name><surname>Renegar</surname><given-names>KB</given-names></name>
<etal/>
</person-group>. <article-title>Bombesin recovers gut-associated lymphoid tissue and preserves immunity to bacterial pneumonia in mice receiving total parenteral nutrition</article-title>. <source>Ann Surg</source>. <year>2000</year>;<volume>231</volume>(<issue>1</issue>):<fpage>1</fpage>-<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr14-0148607111428324">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fukatsu</surname><given-names>K</given-names></name>
<name><surname>Moriya</surname><given-names>T</given-names></name>
<name><surname>Ikezawa</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Interleukin-7 dose dependently restores parenteral nutrition–induced gut associated lymphoid tissue cell loss</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2006</year>;<volume>30</volume>(<issue>5</issue>):<fpage>388</fpage>-<lpage>393</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>